Exscientia's "Centaur Chemist" AI platform computationally sorts through and compares millions of potential small molecules, looking for a handful to synthesize, test and optimize in the lab before selecting a candidate for clinical trials -- all of which enabled the company to help get a cancer drug into trials in just eight months, compared to a more standard four to five years. Quris is working to speed the trial process by testing drugs on miniaturized organs and tissues on a chip that "represent the full genomic diversity of the potential patient population," notes Bentwich, which in turn generates data that can help train its AI platform to predict the clinical safety and efficacy of novel drugs. Lantern Pharma is partnering with digital health care company Deep Lens to use AI to match the right kind of novel molecule with the right patient profile for clinical trials for accelerated clinical trials. That AI-driven approach "can rescue hundreds of millions of dollars in prior drug development costs by ensuring it's being tested on a very specific patient platform," says Panna Sharma, Lantern Pharma's CEO. Exscientia's "Centaur Chemist" AI platform computationally sorts through and compares millions of potential small molecules, looking for a handful to synthesize, test and optimize in the lab before selecting a candidate for clinical trials -- all of which enabled the company to help get a cancer drug into trials in just eight months, compared to a more standard four to five years.